Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.19.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Operating Expenses        
Research and development expenses $ 584,979 $ 611,612 $ 1,804,169 $ 2,477,481
General and administrative expenses 419,028 451,359 1,219,329 1,305,511
Total operating expenses 1,004,007 1,062,971 3,023,498 3,782,992
Operating Loss (1,004,007) (1,062,971) (3,023,498) (3,782,992)
Other Income (Expense)        
Interest expense (2,271) (8,323) (12,973) (154,377)
Interest income 1,503 6,457 10,886 10,163
Total other income (expense) (768) (1,866) (2,087) (144,214)
Net Operating Loss Before Income Tax Benefit (1,004,775) (1,064,837) (3,025,585) (3,927,206)
Income tax benefit 141,251 212,015 442,152 771,332
Net Loss $ (863,524) $ (852,822) $ (2,583,433) $ (3,155,874)
Net Loss per Common Share - Basic and Diluted $ (0.02) $ (0.02) $ (0.07) $ (0.09)
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted 38,798,251 38,674,265 38,716,048 36,869,323